Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSTVAC-F/TRICOM +/- PROSTVAC-V/TRICOM and GM-CSF in Prostate Cancer
NCT00060528Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2003
- Primary completion
- Mar 2006
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of PROSTVAC-F/TRICOM in prostate cancer (PCa) (4 arms), sponsored by National Cancer Institute. Primary endpoint: Number of Participants With an Immune Response at 48 months. Started May 2003; status: completed.
02
Drugs
PROSTVAC-F/TRICOM
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00060528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00060528.